Previous Page  21 / 48 Next Page
Information
Show Menu
Previous Page 21 / 48 Next Page
Page Background

Queratitis Herpética

21

un factor fundamental a considerar para

la necesidad de profilaxis con antivirales

sistémicos. Está demostrado que luego de la

resolución de la patología herpética corneal,

el uso de 12 meses de profilaxis antiviral

con Aciclovir 400mg 2 veces al día vía oral,

reduce la recurrencia en un 40% en patología

ocular por VHS y en un 50% en las queratitis

estromales si se compara con el placebo

24

.

Estudios recientes demuestran hasta un 26%

de cepas resistentes de VHS a Aciclovir en

pacientes con antecedentes de queratitis

estromales tratadas. Los principales factores

pronósticos asociados a la resistencia viral

son el uso mayor a 12 meses de tratamiento

con antivirales en dosis de profilaxis y la

duración mayor de 45 días de la recurrencia.

La resistencia del VHS es factor de riesgo

para compromisos corneales refractarios

25

.

1.

Liesegang TJ. Herpes simplex virus epidemiology and

ocular importance. Cornea 2001.

2.

Benz MS, Glaser JS, Davis JL. Progressive outer retinal

necrosis in immunocompetent patients treated initially

for optic neuropathy with systemic corticosteroids. Am

J Ophthalmol 2003.

3.

Rolinski J, Hus I. Immunological Aspects of Acute and

Recurrent Herpes Simplex Keratitis. J Immunol Res. 2014.

4.

Predictors of recurrent herpes simplex virus keratitis.

Herpetic Eye Disease Study Group. Cornea 2001.

5.

Farooq AV, Shukla D. Herpes simplex epithelial and

stromal keratitis: an epidemiologic update. Surv

Ophthalmol. 2012.

6.

Souza PM, Holland EJ, Huang AJ. Bilateral herpetic

keratoconjunctivitis. Ophthalmology 2003.

7.

Bhat PV, Jakobiec FA, Kurbanyan K, et al. Chronic

herpes simplex scleritis: characterization of 9 cases of an

underrecognized clinical entity. Am J Ophthalmol 2009.

8.

Liesegang TJ. Classification of herpes simplex virus

keratitis and anterior uveitis. Cornea 1999.

9.

Holland EJ, Schwartz GS. Classification of herpes

simplex virus keratitis. Cornea 1999.

10. Cook SD. Herpes simplex virus in the eye. Br J

Ophthalmol 1992.

11. Teng CC. Images in clinical medicine. Corneal dendritic

ulcer from herpes simplex virus infection. N Engl J

Med 2008.

12. Langston DP, Dunkel EC. A rapid clinical diagnostic

test for herpes simplex infectious keratitis. Am J

Ophthalmol 1989.

13. Kaye S, Choudhary A. Herpes simplex keratitis. Prog

Retin. Eye Res 2006.

14. Wilhelmus KR, Coster DJ, Donovan HC, et al. Prognosis

indicators of herpetic keratitis. Analysis of a five-year

observation period after corneal ulceration. Arch

Ophthalmol 1981.

15. Guess S, Stone DU, Chodosh J. Evidence-based treatment

of herpes simplex virus keratitis: a systematic review.

Ocul Surf. 2007.

16. Inoue Y. Immunological aspects of herpetic stromal

keratitis. Semin Ophthalmol 2008.

17. Streilein JW, Dana MR, Ksander BR. Immunity causing

blindness: five different paths to herpes stromal keratitis.

Immunol Today 1997.

18. Suzuki T, Ohashi Y. Corneal endotheliitis. Semin

Ophthalmol 2008.

19. Wilhelmus KR. Therapeutic interventions for herpes

simplex virus epithelial keratitis. Cochrane Database

Syst Rev 2010.

20. A controlled trial of oral acyclovir for iridocyclitis

caused by herpes simplex virus. The Herpetic Eye

Disease Study Group. Arch Ophthalmol 1996.

21. Collum LM, McGettrick P, Akhtar J, et al. Oral acyclovir

(Zovirax) in herpes simplex dendritic corneal ulceration.

Br J Ophthalmol 1986.

22. Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15%

for the treatment of acute herpetic keratitis: background,

effectiveness, tolerability, safety, and future applications.

Ther Clin Risk Manag. 2014.

23. Wilhelmus KR. The treatment of herpes simplex virus

epithelial keratitis. Trans Am Ophthalmol Soc. 2000.

24. Acyclovir for the prevention of recurrent herpes simplex

virus eye disease. The Herpetic Eye Disease Study

Group. N Engl J Med. 1998.

25. Van Velzen M1, van de Vijver DA, van Loenen FB,

Osterhaus AD, Remeijer L, Verjans GM. Acyclovir

prophylaxis predisposes to antiviral-resistant recurrent

herpetic keratitis. J Infect Dis. 2013.

BIBLIOGRAFÍA